Piramal Enterprises To Demerge Healthcare, Financial Services Businesses
Mumbai: Piramal Enterprises will demerge its healthcare and financial services businesses soon, a top company official said on Monday.
“We want to ultimately look at Piramal Enterprises as separate business for pharmaceuticals and financial services. In the medium term we will do that. All our acquisitions, and in some ways moving up in value chains and getting more critical mass are steps towards that,” Piramal Enterprises chairman Ajay Piramal told reporters here.
Declining to give a timeline, Mr Piramal said: “We have not yet fixed time line. I think the Board will decide, but the direction is moving towards that.”
Mr Piramal curtailed his presence in healthcare after he sold erstwhile Piramal Healthcare’s domestic formulations division for $3.7 billion to Abbott in 2010.
The company entered into the finance business through strategic investments and joint ventures.
Piramal Enterprises is growing largely organically with a CAGR of 17 per cent over last the five years.
To boost its product portfolio, Piramal Enterprises on Monday announced acquisition of a portfolio of drugs for spasticity and pain management from UK-based Mallinckrodt for $171 million (around Rs. 1,160 crore) in an all-cash deal.
“We continue to invest in the growth of our pharmaceutical businesses. This would be our seventh pharma acquisition in the last two years, taking our investment for inorganic growth to Rs. 3,000 crore across our pharmaceutical businesses to boost future growth,” Mr Piramal said.
“All these acquisitions are expected to be value accretive and will improve our pharmaceutical segment’s growth. High EBITDA margins of the acquired products are expected to enhance our profitability.”
The company’s UK-based wholly-owned subsidiary Piramal Critical Care has entered into an agreement with Mallinckrodt for acquiring the drugs and may also pay an additional $32 million, depending on financial performance of the acquired assets over the next three years till FY21.
The acquired portfolio includes Gablofen (baclofen), a severe spasticity management product, currently marketed in the US, and two pain management products.
“With this acquisition, we have entered into an attractive niche market. Intrathecal baclofen serves an important medical need to severe spasticity patients. Access to this niche market diversifies our offerings in the US market and allows further growth within the global generic hospital drug market of more than $20 billion in size.”
The company’s 35-40 per cent revenues comes from the US operations, he said, adding it had 24 US FDA inspections, but had no issues with that in last few years.
Disclaimer: This article is for knowledge purpose only. The thoughts and analysis contained in this report are based on data and assumptions derived from external sources, and are presented for information purposes only. Though the authors have used reasonable efforts to compile and analyze the best sources reasonably available to them at the time of writing this report, the authors have not independently verified the completeness or accuracy of the data and assumptions, they do not make any representation regarding the same. Changes in the underlying data or operating assumptions will clearly impact the analysis and conclusions. Therefore, the information contained in this report should not be relied upon without independent investigation, analysis and the authors will not be responsible for any liabilities incurred by any third party as a result of reliance upon such information.
